Related Experiment Video

Updated: Dec 12, 2025

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

5.1K

SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial

Fang Zheng1, Yanwen Zhou2, Zhiguo Zhou3

  • 1Department of Infectious Diseases, The First Hospital of Changsha, Changsha, China.

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|August 8, 2020
PubMed
Abstract

Insights

Novaferon demonstrates significant antiviral activity against SARS-CoV-2 in laboratory settings and COVID-19 patients. This potent antiviral protein drug accelerates viral clearance, supporting its further clinical evaluation.

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • Novaferon is a potent antiviral protein drug.
  • The study evaluated Novaferon's efficacy against COVID-19.
  • The trial was registered under ChiCTR2000029496.

Purpose of the Study:

  • To assess the in vitro antiviral effects of Novaferon against SARS-CoV-2.
  • To evaluate the clinical efficacy of Novaferon in treating COVID-19 patients.
  • To compare Novaferon's effectiveness with Lopinavir/Ritonavir.

Main Methods:

  • In vitro experiments determined Novaferon's inhibition of viral replication and entry.
  • A randomized, open-label trial enrolled 89 COVID-19 patients.
  • Patients received Novaferon, Novaferon plus Lopinavir/Ritonavir, or Lopinavir/Ritonavir.

Main Results:

  • Novaferon inhibited SARS-CoV-2 replication (EC50=1.02ng/ml) and entry (EC50=0.10ng/ml) in vitro.
  • Significantly higher viral clearance rates on day six were observed in Novaferon groups compared to Lopinavir/Ritonavir alone (50.0% and 60.0% vs. 24.1%).
  • Median time to viral clearance was reduced by 3 days in Novaferon-treated groups (6 days) versus Lopinavir/Ritonavir (9 days).

Conclusions:

  • Novaferon exhibits significant anti-SARS-CoV-2 activity both in vitro and in clinical settings.
  • Novaferon treatment led to accelerated viral clearance in COVID-19 patients.
  • Further clinical evaluation of Novaferon for COVID-19 treatment is warranted.
Keywords:
Aerosolized inhalationAntiviral drugCOVID-19Lopinavir/RitonavirNovaferonSARS-CoV-2Viral clearance

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses05:49

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

2.3K

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
71
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
122
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.9K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
105